Assessment of Biomarkers in Ectopic Pregnancy

Learn more about:
Related Clinical Trial
Reproductive Outcomes After a Previous Episode of Tubal Ectopic Pregnancy in Patients Managed Expectantly and Surgically Relationship Between Ectopic Pregnancy and Thyroid Disorders Medical Treatment in Ectopic Tubal Pregnancy Evaluation of Different Doses of Letrozole in Ectopic Pregnancy Evaluation of Ipsilateral Tubal Patency After Conservative Medical or Surgical Treatment. Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task Expectant Management of Ectopic Pregnancy Psychological Impact of Pregnancy of Unknown Location Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility Hysteroscopic Metroplasty in Unexplained Infertile Women With Dysmorphic Uterus Cornual Wedge Resection Outcome Pregnancies of Uncertain Location or Viability Research Randomized Population-Based Study on Chlamydia Trachomatis Screening Sonographic Assessment and Visualization of Ectopics in Emergency Medicine Kisspeptin Levels in Early Pregnancy RCT for Women With a Persisting Pregnancy of Unknown Location Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy Vitamin D in Ectopic Pregnancies Laparoscopic Tubal Preservation Surgery BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success The Correlation Between Uterine Endometrial Pattern and Ectopic Pregnancy Adnexal Mass After Methotrexate Treatment for Ectopic Pregnancies The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy Methotrexate Treatment for Ectopic Pregnancy Comparison of Two Different Approaches in the Surgical Treatment of Tubal Ectopic Pregnancy Two-Dose Methotrexate for Ectopic Pregnancy Ectopic Pregnancy Biomarkers The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy? Risk Factors of Ectopic Pregnancy Assessment of Biomarkers in Ectopic Pregnancy Risk of Ectopic Pregnancy and Variation of Luteal Estradiol and Progesterone Levels in IVF

Brief Title

Assessment of Biomarkers in Ectopic Pregnancy

Official Title

The Assessment of Biomarkers in Ectopic Pregnancy

Brief Summary

      To further develop a patient care pathway (incorporating a statistical model which uses the
      values of biomarkers) in routine clinical practice that will aid the diagnosis and management
      of women with an ectopic pregnancy.
    

Detailed Description

      Purpose and design-There is a need for the patient care pathway to evolve in order to aid and
      improve the diagnosis and management of women with a pregnancy of unknown location (PUL) and
      ectopic pregnancy (EP). There is potential for this to be achieved by the incorporation of a
      statistical model that uses one or more novel markers identified by this study. These markers
      may replace or add to the effectiveness of markers used in the current statistical model.

      Recruitment-200 patients. Inclusion: Patients attending the Early Pregnancy Unit (EPU) in the
      first trimester with a PUL or ectopic pregnancy on trans-vaginal ultrasound scan between the
      ages of 18-50 years. Exclusion: Patients diagnosed with cancer, presence of acute medical
      condition, patients aged less than 18 years, patients who cannot give fully informed study
      consent.

      Consent - Posters will advertise the study. Patients in EPU will be invited to the study by a
      member of the clinical care team. Written consent will be required for all aspects of the
      study other than for 3-dimensional scanning of PUL and EP patients, where verbal consent will
      be obtained. Patients will be given at least 24 hours to consider whether they wish to
      participate.

      Confidentiality - The Chief Investigator will preserve the confidentiality of participants
      taking part in the study and is registered under the Data Protection Act. Patient consent
      forms will be stored securely within the study file. All patient identifiable information,
      where required, will be stored electronically on National Health Service (NHS) approved
      computers, accessible only by personnel involved in the study via password.

      Conflict of interest - None involved in the study have a conflict of interest.

      Dissemination of results - No patient identifiable information will be included in the
      research report or publication. Anonymised results will be disseminated to scientific
      community by means of publication in peer-reviewed literature and presented at national and
      international meetings.
    


Study Type

Observational


Primary Outcome

Novel biomarkers for Ectopic Pregnancy prediction and diagnosis

Secondary Outcome

 microRNA as a biomarker

Condition

Ectopic Pregnancy

Intervention

Management of Ectopic Pregnancy

Study Arms / Comparison Groups

 Ectopic Pregnancy
Description:  Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

200

Start Date

November 18, 2019

Completion Date

December 31, 2025

Primary Completion Date

December 31, 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Patients attending the Early Pregnancy Unit (EPU) in the first trimester (up to 14
             weeks gestation) with a PUL or ectopic pregnancy on trans-vaginal ultrasound scan
             between the ages of 18 and 50 years.

          -  Patients attending the gynaecology unit for a surgical termination of pregnancy or for
             a salpingo-oophorectomy.

        Exclusion Criteria:

          -  Patients diagnosed with cancer, presence of an acute medical condition, patients aged
             less than 18 years, patients who cannot give fully informed study consent (language or
             learning impairment), presence of a viable intrauterine pregnancy and presence of
             miscarriage.

          -  Exclusion to fallopian tube samples - presence of any ectopic pregnancy that does not
             require operative salpingectomy.

          -  Exclusion to peritoneal washings - presence of any ectopic pregnancy that does not
             require access to the peritoneal cavity as part of management.

          -  Exclusion to trophoblast tissue sampling - presence of an ectopic pregnancy that does
             not require surgical removal.
      

Gender

Female

Ages

18 Years - 50 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Tom Bourne, MBBS, PhD, MRCOG, 0044 203 313 5131, [email protected]

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT04176549

Organization ID

18HH4883


Responsible Party

Sponsor

Study Sponsor

Imperial College London

Collaborators

 Imperial College Healthcare NHS Trust

Study Sponsor

Tom Bourne, MBBS, PhD, MRCOG, Principal Investigator, Imperial College London


Verification Date

July 2022